Literatura científica selecionada sobre o tema "Cancer sur puce"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Cancer sur puce".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Artigos de revistas sobre o assunto "Cancer sur puce"
Bertucci, François, Pascal Finetti, Nathalie Cervera e Daniel Birnbaum. "Classification pronostique du cancer du sein et profils d’expression génique sur puces à ADN". médecine/sciences 24, n.º 6-7 (junho de 2008): 599–606. http://dx.doi.org/10.1051/medsci/20082467599.
Texto completo da fonteKammerer-Jacquet, Solène-Florence, Frédéric Dugay, Laurence Cornevin, Angélique Brunot, Julien Dagher, Gregory Verhoest, Karim Bensalah et al. "Étude par analyse chromosomique sur puces à ADN d’une série de 45 cancers du rein à cellule claires métastatiques : caractérisation des profils génomiques prédictifs de la réponse ou de la résistance à un traitement antiangiogénique (sunitinib)". Morphologie 100, n.º 330 (setembro de 2016): 184–85. http://dx.doi.org/10.1016/j.morpho.2016.07.054.
Texto completo da fonteTeses / dissertações sobre o assunto "Cancer sur puce"
Baka, Zakaria. "Élaboration de cancers sur puce pour des applications en thérapies anticancéreuses". Electronic Thesis or Diss., Université de Lorraine, 2023. http://www.theses.fr/2023LORR0175.
Texto completo da fonteOvarian cancer is a major public health issue. Moreover, new treatments still face very high failure rates. This is mainly due to the unreliability of conventional preclinical models such as 2D cell culture. Thus, new tools based on 3D cell culture have emerged such as spheroids and organoids. However, these models have their own limitations (cost, difficulty of application). 3D bioprinting is a new approach to create tunable and reproducible tumor models. However, very few bioprinted tumor models have been reported so far. Besides the “third dimension”, it is important to consider the dynamic conditions of the tumor environment. This has been possible for some years now thanks to microfluidics-based cancer-on-a-chip technology. However, this technology currently does not simulate the drug vascular transport before its interaction with the tumor cells. In this PhD project, we set out to create a dynamic, three-dimensional model of ovarian cancer by combining 3D bioprinting and microfluidics. First, 3D bioprinting was used to create the tumor structure itself. For that, we formulated a bio-ink comprising SKOV-3 ovarian cancer cells and MeWo cancer fibroblasts embedded in a gelatin – alginate hydrogel. The bioprinted tumor structures were then characterized by various techniques to demonstrate their viability and biological relevance. Their response to anticancer drug cisplatin was also assessed. In the second step, we integrated the bioprinted tumor model into a microfluidic support for culture under physiological flow. This support was also intended to simulate the drug's vascular transport prior to interaction with the tumor tissue. We then used computational fluid dynamics to design an improved version of the first system. The aim of this improved version was to simultaneously assess multiple drug concentrations. This PhD project demonstrated the ability of 3D bioprinting to create viable and functional ovarian tumor models. It has also brought interesting research prospects with regard to the possibilities of combining 3D bioprinting and microfluidics to improve preclinical modeling of ovarian tumors
Saias, Laure. "Laboratoires-sur-puce pour l'analyse cellulaire : tri de cellules tumorales circulantes et culture de neurones". Paris 6, 2009. http://www.theses.fr/2009PA066684.
Texto completo da fonteBourg, Samantha. "Développement de systèmes miniaturisés à base d’aptamères pour la détection de biomarqueurs de cancer". Thesis, Paris Sciences et Lettres (ComUE), 2019. http://www.theses.fr/2019PSLEC020.
Texto completo da fonteCommon methods of cancer diagnosis are invasive, expensive and rarely allow early cancer diagnosis. The discovery of cancer biomarkers present in the early stage of the disease, well before the development of symptoms make them interesting candidate for early cancer diagnosis. These markers are still not widely used, particularly because of their low concentration in healthy patient samples, but also because of their lack of specificity taken individually. Nowadays, clinical analyses for the diagnosis are performed by dividing samples and separate measurements of the concentration of the various clinically relevant analytes. In this context, the development of devices for the simultaneous detection of these markers in biological fluids is a real challenge. In addition, the miniaturization of measurement devices and their integration on a chip opens the way to automated analysis units that can be transported to the bedside and meet the needs of hospitals for fast, low-volume, low-cost, high throughput, sensitive and specific analyses. The objective of this thesis is to develop methods for the localized immobilization of selective ligands based on molecular recognition (aptamers) on different microsystem materials for the simultaneous detection of several biomarkers. Aptamers are a new classe of synthetic DNA/RNA molecules, known for their high affinity and excellent specificity for a selected target or family of targets. They also have the advantage of being easy to handle at room temperature and easily regenerated after denaturation. Despite these advantages, very few publications have been published on aptamer-based technologies for the selective extraction and analysis of biomarker traces in microfluidic devices. The creation of such localized zones ensures the overconcentration of target analytes to improve detection performance
Veith, Irina. "Lung Cancer On-Chip for Immunotherapy Response Profiling Apoptosis Mapping in Space and Time of 3D Tumor Ecosystems Reveals Transmissibility of Cytotoxic Cancer Death". Thesis, université Paris-Saclay, 2020. http://www.theses.fr/2020UPASL036.
Texto completo da fonteNon-small cell lung cancer (NSCLC) is one of the few tumor diseases, with melanoma and vesical carcinoma, for which immuno-oncology drugs led to a therapeutic revolution. Only 20 to 30% of the NSCLC patients benefit from immune checkpoint inhibitors (ICI) monotherapy with durable responses, while combinations led up to 40% of long responder patients. Our study aims to better characterize the modulation of the tumor microenvironment upon ICI treatment, plus or minus concurrent chemotherapy, in order to guide more compelling immunotherapy strategies. Inspired by the organ-on-a-chip technology, we implemented the reconstitution ex vivo of a simplified immunocompetent lung tumor microenvironment by performing 3D co-cultures in microfluidic devices. This approach allowed us to perform live-imaging and quantification of the effects of ICI on the tumor ecosystem.The design of the chip consists of three parallel micro-chambers, separated by micro-pillars that allow the confinement of a biomimetic hydrogel in the central channel by capillarity. By co-culturing autologous NSCLC cells and cytotoxic T lymphocytes (harvested from the TILs of the same patient and furtherly amplified in vitro) we could recapitulate, visualize and quantify an efficient and specific cytotoxic activity of the T cells against the autologous cancer cells. For this purpose, we developed a novel algorithm that could localize the cancer cells and, thanks to a fluorescent reporter of the caspase activity, measure their death in a time- and space-specific manner. In these 3D co-cultures the cytotoxic activity of T cells was enhanced by the treatment with PD-1 inhibitor and PD-L1 inhibitor, therefore reconstituting on-chip an ICI response. Furthermore, this method allowed us to extract a parameter, the potential of death induction, which mathematically estimates the “contagiousness of death” by computing the proximity in space and time of death signals. Interestingly, this analysis revealed us that the death of cancer cells caused by either chemotherapy or cytotoxic T cells is contagious, whereas in control conditions the cancer cells death is stochastic. This observation may have biological and clinical implications, for instance regarding the bystander effect, observed after radiotherapy treatment. Furthermore, in order to have a molecular insight on the impact of the co-culture on T cells, in presence or absence of ICI, we analyzed by flow cytometry the expression of several T cell markers. After 3 days of co-culture on chip, the T cells showed an increased expression of activation markers, such as CD69 and CD25, as well as an increased expression of exhaustion markers, notably PD-1, TIGIT, TIM-3, LAG-3, CD137 and OX-40. The coupling of image analysis and the study of T cell plasticity, allowed us to associate for the first time the finely quantified cytotoxic activity of the T cells and their activation/exhaustion status and describe a responsive phenotype to immunotherapies. In this thesis, we demonstrated that the tumor-on-chip is suitable to evaluate the efficacy of immune checkpoint inhibitors, to potentially assess the effect of combined drugs and to study the mechanisms of cancer cell primary resistance
Miollis, Frédérick de. "Développement d’un système de culture in vitro 3D et microfluidique pour étudier les interactions tumeur-stroma et la résistance aux drogues de l’adénocarcinome du pancréas". Thesis, Lille, 2021. http://www.theses.fr/2021LILUI015.
Texto completo da fontePancreatic cancer is one of the deadliest cancers with an extremely poor prognosis. In 2020, the 5-year survival rate remains very low (only 3 to 9%) and the median is less than 6 months. Despite significant progress in the patient care, current therapies do not have the expected effectiveness. This is due to the strong chemoresistance observed in this cancer. The key factor of this resistance is the complex tumor microenvironment mainly composed of stroma and a dense extracellular matrix limiting the access of therapies to the tumor. The current models’ limitations, particularly in terms of physiological relevance, are a major obstacle in understanding this chemoresistance. In response to this issue, researchers are turning to different approaches by developing brand new models that are alternatives to those already available (in vitro and in vivo).The objectives of this work were: (i) to develop an in vitro 3D microfluidic culture device allowing to reproduce the tumor microenvironment both biologically and mechanically, as well as to model the flows and mass transport present in a pancreatic tumor, and (ii) to approach the morphological changes of the co-culture by studying epithelio-mesenchymal markers and to study the impact of FOLFIRINOX chemotherapy in this model.First, we have shown numerically and experimentally the feasibility of such an in vitro model. The chosen extracellular matrix is a combination of collagen I and hyaluronic acid creating a rigid structure close to in vivo conditions. It allows long-term culture maintenance under the effect of the perfusion as well as the activation of pancreatic stellate cells. The chosen perfusion rate allows to apply an interstitial flow in the model equivalent to the one observed in the in vivo microenvironment, inducing hydrostatic pressure and shear stress on the cancerous cells.Then, we demonstrated the biological contribution of this model by showing an increased chemoresistance to the FOLFIRINOX protocol of tumor cells both in mono- and in co-culture in the microfluidic device. We also show the establishment of a process presenting characteristics of epithelial-mesenchymal transition and a possible promotion of a dedifferentiated phenotype of tumor cells by activated pancreatic stellate cells.In conclusion, we present in this thesis an original microfluidic model allowing to mimic a tumor (co-culture of epithelial and mesenchymal cells) and to study the kinetics of a complex multidrug chemotherapy. In the future, the device should allow us to further study the mechanisms of drug resistance and tumor-stroma interactions in pancreatic cancer
Giusiano-Courcambeck, Sophie. "Rôle de TP53INP1 dans l'histoire naturelle du cancer prostatique". Thesis, Aix-Marseille, 2012. http://www.theses.fr/2012AIXM5007/document.
Texto completo da fonteProstate cancer (PC) is the most common malignancy in France and one of the most frequent leading causes of cancer-related death in men in industrialized countries. Even with aggressive screening, approximately one-third of patients believed to have localized PC will already have micro-metastatic disease at the time of definitive local therapy. These patients initially respond to androgen ablative therapy, but with time, their tumors ultimately become unresponsive and recur within 2 years as castration-resistant prostate cancer (CRPC). Recently, docetaxel-based regimens have shown improved survival in men with CRPC in phase III studies. However, the median overall survival was prolonged for only 2-3 months, and thus development of new therapeutic approaches that target relevant signaling pathways are essential to restore the androgen-sensitivity of CRPC. We showed, using tissue micro-array (TMA) analysis, that over-expression of Tumor Protein 53-Induced Nuclear Protein 1 (TP53INP1), a cell stress response protein, is a worse prognostic factor in PC, particularly predictive of biological cancer relapse. We also we found that TP53INP1 protein expression decreases during castration therapy (CT) and significantly increases in human CRPC. TP53INP1 mRNA was also significantly increased in castration-resistant (CR) tumors of LNCaP xenograft compared to the castration-sensitive (CS) taken before CT. We developed and world-wide patented one antisense oligonucleotide (ASO) targeting TP53INP1 (PCT/IB2011/054555). Treatment of LNCaP and C4-2 cells in vitro with TP53INP1 ASO downregulates TP53INP1 protein level, inhibits proliferation and induces apoptosis
Capítulos de livros sobre o assunto "Cancer sur puce"
Tembe Fokunang, Estella, Mbong Grace Annih, Lem Edith Abongwa, Manju Evelyn Bih, Tchadji Mayoudom Vanessa, Dobgima John Fomnboh e Charles Fokunang. "Medicinal Mushroom of Potential Pharmaceutical Toxic Importance: Contribution in Phytotherapy". In Functional Food [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.103845.
Texto completo da fonte